MabPlex International Announces Appointment of Dr. Yongjian Wu (Ph.D.) as Chief Operating Officer of MabPlex USA

Share Article

MabPlex International Ltd. (MabPlex) has appointed Yongjian Wu, Ph.D as Chief Operating Officer (COO) of MabPlex USA. Dr. Wu is a senior biopharmaceutical professional with over 18 years of Chemistry, Manufacturing and Controls (CMC) development experience in biologics, including monoclonal antibodies, antibody-drug conjugates and biosimilars.

News Image
We are very pleased that Dr. Wu has joined the MabPlex team. His extensive experience will play an important role in advancing MabPlex’s top-quality, global biopharmaceutical and biotechnology services while helping accelerate new drug development projects worldwide.

MabPlex International, Ltd. (MabPlex), a leading, fully integrated, Contract Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China and the United States, today announced the appointment of Yongjian Wu, Ph.D. as Chief Operating Officer (COO) of MabPlex USA.

Dr. Wu’s appointment will add to the overall strength of MabPlex offering a top quality service to global biopharmaceutical and biotechnology companies, while helping to accelerate new drug development projects worldwide.

“MabPlex offers one of the few globally integrated service platforms with high production capacity, something that is unique in our industry,” said Dr. Wu.

“The company employs a world-class professional team with diverse project experience in Asia and abroad. With robust technical and quality systems, large-capacity current Good Manufacturing Practice (cGMP) facilities, and a wealth of experience in successful project execution and Investigational New Drug application (IND) submissions, MabPlex truly provides a one-stop CDMO service for biologics, especially for antibody-drug conjugates (ADCs). I am honored and excited to join MabPlex and hope to contribute to the growth of the company while further enhancing our capabilities to serve the international market,” said Dr. Wu concluded.

Extensive experience
Dr. Wu has more than 18 years of global biopharmaceutical experience. Before joining MabPlex, Dr. Wu worked at Bayer, BioMarin, Genentech and Tanvex, with both internal manufacturing and quality organizations for the production of preclinical/clinical and commercial-ready materials, as well as with external Contract Research Organization (CRO) for preclinical, bioanalytical and clinical development of pipeline projects. He has advanced numerous new drug development projects from early research/preclinical stage to IND and Biologics License Applications (BLA), authoring regulatory filings and interacting with agencies during face to face meetings and inspections.

Dr. Wu obtained his Ph.D. in Immunology at the University of Toronto, Canada, with Professor Nobumichi Hozumi, MD, Ph,D. He did his postdoctoral training in the Department of Neurobiology at Stanford University, Stanford, California with Professor Eric Manvers Shooter MA, Sc.D., D.Sc., FRS.

About MabPlex
MabPlex International Ltd (MabPlex), a leading and fully integrated, global Contract Development and Manufacturing Organization (CDMO), offers an advanced biologics platform and comprehensive and integrated solutions to global (bio-) pharmaceutical developers. Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering high quality services from biologics drug development to commercial manufacturing. MabPlex currently has over 60,000 square meters of R&D and production facilities, a total of 9 monoclonal antibody (mAb) Drug Substance (DS) production lines, 2 Antibody-drug Conjugate (ADC) DS production lines, as well as mAb formulation and ADC formulation lines. The commercial production service is designed to help customers accelerate the progress of clinical trials and support market launch.

MabPlex has established a talented team of more than 400 employees provideding Contract Development and Manufacturing Organization (CDMO) services to more than 40 pharmaceutical companies around the world resulting in more than 12 Investigational New Drug application (IND) approvals with the United States Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA) and China's National Medical Products Administration (NMPA). For more information, please visit our website at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cheryl Tuck
Visit website